Farmaceutica R
Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics. In addition, the company provides packaging materials; and logistics, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headqua… Read more
Farmaceutica R (RMAH) - Net Assets
Latest net assets as of September 2025: RON75.19 Million RON
Based on the latest financial reports, Farmaceutica R (RMAH) has net assets worth RON75.19 Million RON as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON366.64 Million) and total liabilities (RON291.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON75.19 Million |
| % of Total Assets | 20.51% |
| Annual Growth Rate | -1.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.92 |
Farmaceutica R - Net Assets Trend (2020–2024)
This chart illustrates how Farmaceutica R's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Farmaceutica R (2020–2024)
The table below shows the annual net assets of Farmaceutica R from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | RON74.94 Million | +5.76% |
| 2023-09-30 | RON70.86 Million | +3.55% |
| 2022-09-30 | RON68.43 Million | +0.31% |
| 2021-09-30 | RON68.22 Million | -14.54% |
| 2020-09-30 | RON79.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Farmaceutica R's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON23.89 Million | 31.88% |
| Other Components | RON51.05 Million | 68.12% |
| Total Equity | RON74.94 Million | 100.00% |
Farmaceutica R Competitors by Market Cap
The table below lists competitors of Farmaceutica R ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Altshuler Shaham Financial LTD
TA:ALTF
|
$3.04 Million |
|
City Steel Public Company Limited
BK:CITY
|
$3.05 Million |
|
Taiwan Green Environment Technology Inc.
TWO:5205
|
$3.05 Million |
|
APPLIED MATERIALS
MU:AP2
|
$3.05 Million |
|
Ahlada Engineers Limited
NSE:AHLADA
|
$3.04 Million |
|
Stradim Espace Finances SA
PA:ALSAS
|
$3.04 Million |
|
Gafisa S.A
SA:GFSA3
|
$3.04 Million |
|
Trinitan Metals and Minerals
JK:PURE
|
$3.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Farmaceutica R's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,859,551 to 74,940,956, a change of 4,081,405 (5.8%).
- Net income of 6,962,186 contributed positively to equity growth.
- Dividend payments of 6,290,000 reduced retained earnings.
- Other factors increased equity by 3,409,219.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON6.96 Million | +9.29% |
| Dividends Paid | RON6.29 Million | -8.39% |
| Other Changes | RON3.41 Million | +4.55% |
| Total Change | RON- | 5.76% |
Book Value vs Market Value Analysis
This analysis compares Farmaceutica R's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-09-30 | RON0.75 | RON0.87 | x |
| 2021-09-30 | RON0.72 | RON0.87 | x |
| 2022-09-30 | RON0.72 | RON0.87 | x |
| 2023-09-30 | RON0.74 | RON0.87 | x |
| 2024-09-30 | RON0.79 | RON0.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Farmaceutica R utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.29%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.94%
- • Asset Turnover: 1.98x
- • Equity Multiplier: 5.02x
- Recent ROE (9.29%) is below the historical average (17.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 47.31% | 8.56% | 1.81x | 3.06x | RON29.79 Million |
| 2021 | 10.60% | 1.52% | 1.90x | 3.68x | RON410.80K |
| 2022 | 8.49% | 1.08% | 1.87x | 4.18x | RON-1.03 Million |
| 2023 | 10.16% | 1.21% | 1.88x | 4.46x | RON115.69K |
| 2024 | 9.29% | 0.94% | 1.98x | 5.02x | RON-531.91K |
Industry Comparison
This section compares Farmaceutica R's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.